Supplementary Figure 3 from A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

PDF file - 624K, Relationship between sonidegib area under the plasma concentration-time curve on day 15 and the incidence of grade 3/4 creatine kinase elevation.